Ginkgo Bioworks Holdings Inc DNA.N, DNA is expected to show a rise in quarterly revenue when it reports results on May 6 for the period ending March 31 2025
The Boston Massachusetts-based company is expected to report a 2.0% increase in revenue to $38.696 million from $37.94 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ginkgo Bioworks Holdings Inc is for a loss of $1.77 per share.
The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 4 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, above its last closing price of $7.04.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -1.49 | -1.77 | -2.00 | Missed | -13 |
Sep. 30 2024 | -2.87 | -2.73 | -0.94 | Beat | 65.5 |
Jun. 30 2024 | -3.20 | -3.12 | -2.80 | Beat | 10.3 |
Mar. 31 2024 | -3.36 | -3.33 | -3.20 | Beat | 4 |
Dec. 31 2023 | -4.17 | -3.87 | -4.40 | Missed | -13.8 |
Sep. 30 2023 | -3.34 | -3.43 | -6.40 | Missed | -86.7 |
Jun. 30 2023 | -2.99 | -3.37 | -3.60 | Missed | -6.8 |
Mar. 31 2023 | -3.44 | -3.60 | -4.40 | Missed | -22.2 |
This summary was machine generated May 2 at 22:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。